References
- Compston A, Coles A. Multiple sclerosis. Lancet359, 1221–1231 (2002).
- Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty- five years of follow-up. Brain116, 117–134 (1993).
- Weinshenker BG, Bass R, Rice GP et al. The natural history of multiple sclerosis: a geographically based study I. Clinical course and disability. Brain112, 133–146 (1989).
- McDonald WI, Compston A, Edan G et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol.50, 121–127 (2001).
- Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol.121, 944–949 (2003).
- Nilsson P, Larsson E-M, Maly-Sundgren P, Perfekt R, SandbergWollheim M. Predicting the outcome of optic neuritis evaluation of risk factors after 30 years of follow-up. J. Neurol. (2005) (In Press).
- O’Riordan JI, Thompson DP, Kingsley DP et al. The prognostic value of brain MRI in clinically-isolated syndromes of the CNS. A 10-year follow-up. Brain121, 495–503 (1998).
- Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology58(2), 169–178 (2002).
- Oger J, Freedman M. Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in multiple sclerosis. Can. J. Neurosci.26, 294 (1999).
- Freedman MS, Blumhardt LO, Brochet B et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult. Scler.8, 19–23 (2002).
- Rieckmann P, Toyka KV, The Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG). Escalating therapy of multiple sclerosis. Eur. Neurol.42, 121–127 (1999).
- Weinstock-Guttman B, Ransohoff RM, Kinkel RP et al. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol.37, 7–15 (1995).
- Runkel L, Meier W, Pepinsky RB et al. Structural and functional differences between glycosylated and non-glycosylated forms of human IFN-β. Pharm. Res.15, 641–649 (1998).
- Rothuizen LE, Buclin T, Spertini F et al. Influence of interferon-β1a dose frequency on PBMC cytokine secretion and biologic effect markers. J. Neuroimmunol.99, 131–141 (1999).
- Coclet-Ninin J, Dayer JM, Burger D. Interferon-β not only inhibits interleukin-1 β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Net.8, 345–349 (1997).
- Munafo A, Trinchard-Lugan I, Nguyen TXQ et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon-β1a after intramuscular and subcutaneous administration. Eur. Neurol.5, 187–193 (1998).
- Deisenhammer F, Mayringer I, Harvey J et al. A comparative study of the relative bioavailability of different interferon-β preparations. Neurology54, 2055–2060 (2000).
- Serono. Product information.
- Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon-β1a in patients with multiple sclerosis. (Submitted).
- The IFN-B Multiple Sclerosis Study Group. Interferon-β1b is effective in relapsing remitting multiple sclerosis: I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology43, 655–661 (1993).
- Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFN-B Multiple Sclerosis Study Group. Interferon-β1b is effective in remitting and relapsing multiple sclerosis: II. MRI analysis results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology43, 662–667 (1993).
- Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon-β1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39, 285–294 (1996).
- PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon-β1a in relapsing/remitting multiple sclerosis. Lancet352, 1498–1504 (1998).
- Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing–remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-β1a Subcutaneously in Multiple Sclerosis. Ann. Neurol.46, 197–206 (1999).
- Francis G. Benefit-risk assessment of interferon-β therapy for relapsing multiple sclerosis. Expert Opin. Drug Saf.3, 289–303 (2004).
- Paty DW. Long-term observational efficacy and safety follow-up of the PRISMS cohort. Mult. Scler.9(Suppl. 1), S138 (2003).
- Kappos L, Sandberg-Wollheim M, Uitdehaag B et al. Long-term outcomes of patients treated with IFN-β1a compare favourably to natural history: 8-year follow-up of the PRISMS cohort. J. Neurol.251(Suppl. 3), 191 (2004).
- Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357, 1576–1582 (2001).
- SPECTRIMS Study Group: randomized controlled trial of interferon-β1a in secondary progressive MS: clinical results. Neurology56, 1496–1504 (2001).
- Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-β1a in secondary progressive MS: MRI results. Neurology56, 1505–1513 (2001).
- The Once Weekly Interferon for MS Study Group: evidence of interferon-β1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology53, 679–686 (1999).
- Andersen O, Elovaara I, Färkkilä M et al. Multicentre, randomised, double-blind, placebo-controlled, Phase III study of weekly, low dose, subcutaneous interferon-β1a in secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry75, 706–710 (2004).
- Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon-β1a treatment regimens in MS: the EVIDENCE trial. Neurology59, 1496–1506 (2002).
- Clanet M, Radue EW, Kappos L et al. A randomized, double-blind, dose-comparison study of weekly interferon-β1a in relapsing MS. Neurology59, 1507–1517 (2002).
- The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β1a in relapsing MS. Neurology56, 1628–1636 (2001).
- Cohen JA, Cutter GR, Fischer JS et al. Benefit of interferon-β1a on MSFC progression in secondary progressive MS. Neurology59, 679–687 (2002).
- Goodkin DE. Interferon-β1b in secondary progressive MS: clinical and MRI results of a 3-year randomised controlled trial. Neurology54, 2352 (2000).
- European Study Group on Interferon-β1b in secondary progressive MS: placebo-controlled multi-centre randomised trial of interferon-β1b in treatment of secondary progressive multiple sclerosis. Lancet352, 1491–1497 (1998).
- Kappos L, Polman C, Pozzilli C et al. Final analysis of the European multicenter trial on IFN-β1b in secondary-progressive MS. Neurology57, 1969–1975 (2001).
- Miller DH, Molyneux PD, Barker GJ et al. Effect of Interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann. Neurol.46, 850–859 (1999).
- Alam J, Goelz S, Rioux P et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon-β1a (IFN-β1a) products administered intramuscularly in healthy male and female volunteers. Pharmaceut. Res.14, 546–549 (1997).
- Munafo A, Trinchard-Lugan I, Nguyen TXQ, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon-β1a after intramuscular and subcutaneous administration. Eur. Neurol.5, 1–7 (1998).
- Stürzebecher S, Maibauer R, Heuner A et al. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J. Interferon Cytokine Res.19, 1257–1264 (1999).
- Durelli L, Verdun E, Barbero P et al. Every-other-day interferon-β1b versus once-weekly interferon-β1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet359, 1453–1460 (2002).
- Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon-β1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med.343, 898–904 (2000).
- Bertolotto A, Gilli F, Sala A et al. Persistent neutralizing antibodies abolish the interferon-β bioavailability in MS patients. Neurology60, 634–639 (2003).
- Soelberg Sorensen P, Ross C, Clemmesen KM et al. Clinical importance of neutralising antibodies against interferon-β in patients with relapsing-remitting multiple sclerosis. Lancet362, 1184–1191 (2003).
- Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology41, 685–691 (1991).
- Pliskin NH, Hamer DP, Goldstein DS et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon-β1b. Neurology47, 1463–1468 (1996).
- Weinstein A, Schwid SR, Schiffer RB et al. Neuropsychological status in multiple sclerosis after treatment with glatiramer acetate (Copaxone). Arch. Neurol.56, 319–324 (1999).
- Rudick RA, Antel J, Confavreux C et al. Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force. Ann. Neurol.42, 379–382 (1997).
- Cutter GR, Baier MS, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain122, 101–112 (1999).
- Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Assessment Task Force. Mult. Scler.5, 244–250 (1999).
- Zivadinov R, Sepcic J, Nasuelli D et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. JNNP70, 773–780 (2001).
- Rudick RA, Fisher E, Lee J-C et al. Use of brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology53, 1698–1704 (1999).
- Peyser JM, Rao SM, LaRocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Arch. Neurol.47, 94–97 (1990).
- Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon-β1a in relapsing multiple sclerosis. Ann. Neurol.48, 885–892 (2000).
- Summary Basis of Approval. FDA official document for license of interferon-β1a (Avonex). (1995).
- Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon-β therapy and their management. Neurology53, 1622–1627 (1999).
- Sandberg-Wollheim M, Bever C, Carter J et al. Comparative tolerance of IFN-β1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J. Neurol. (2004) (In Press).
- Francis GS, Grumser Y, Alteri E et al. Hepatic reactions during treatment of multiple sclerosis with interferon-β1a: incidence and clinical significance. Drug Saf.26, 815–827 (2003).
- Yoshida EM, Rasmussen SL, Steinbrecher UP et al. Fulminant liver failure during interferon-β treatment of multiple sclerosis. Neurology56, 1416 (2001).
- Miller DH, Khan OA, Sheremata WA et al. A controlled trial of Natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348, 15–23 (2003).
- The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study. Neurology63, 1788–1795 (2004).
Website
- Summary basis of approval. FDA official document for license of interferon-β1a (Avonex®; 1995) www.fda.gov/cder/biologics/products/IFNbbio051796.htm (Accessed December 2004)